MAP2K7 and neoplasm: Three patients of all had received a prior systemic tumor therapy, one patient with irHypophysitis and one patient of the other irAE group had received BRAF/MEK‐inhibitor therapy before, and one patient of the control group with other irAE had received tyrosine kinase inhibitor therapy, previously.